Copyright medicaldialogues
Hyderabad: Pharma firm NATCO Pharma Limited has launched Everolimus tablets 1mg in the US. The product is a generic version of Zortress by Novartis.As per the BSE filing, NATCO’s marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, plans to launch the product immediately in the U.S. market.Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023.Read also: Natco Gets SC Nod to Launch Generic Risdiplam at 80% Lower Price, Roche Appeal DismissedNATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.Natco is a R&D oriented, and a science driven, Oncology company in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.
